Bio-Techne Reports Mixed Q4 as $11.3B Merck Deal Looms
Event summary
- Bio-Techne's Q4 organic revenue grew 3% to $321.2M, but full-year revenue remained flat at $1.2B.
- GAAP EPS improved to $0.35 from $(0.11) YoY, while adjusted EPS dipped slightly to $0.52.
- Diagnostics segment saw 8% organic growth in Q4, offset by a 1% decline in Protein Sciences.
- Company agreed to be acquired by Merck KGaA for $73/share, valuing Bio-Techne at ~$11.3B.
The big picture
Bio-Techne's mixed results reflect broader challenges in the life sciences tools sector, where diagnostic growth often outpaces research reagent demand. The $11.3B Merck deal signals consolidation pressure as larger players seek scale to compete with Thermo Fisher and Danaher. Watch whether Bio-Techne's profitability initiatives can offset margin pressures from product mix shifts.
What we're watching
- Integration Challenges
- How Merck will integrate Bio-Techne's specialized protein and diagnostic businesses into its own operations.
- Segment Performance
- Whether Diagnostics can sustain high-single-digit growth amid Protein Sciences' volume pressures.
- Regulatory Approvals
- The pace at which Merck completes the acquisition, given typical antitrust review timelines for life sciences deals.
Related topics